In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more. Read the full coverage here: COVID-19 patients at risk for neurological complications 1 year post-infection Patients with back pain benefited from at-home VR program FDA requests further analysis of Supernus Parkinson's treatment Erenumab not effective at reducing pain in trigeminal neuralgia Multiple factors indicate need for additional care after concussion References: Andersen ASS, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00294-0. Hou BQ, et al. Clin J Sport Med. 2022;doi:10.1097/JSM.0000000000001057. Maddox T, et al. At-home virtual reality program for chronic low back pain: Durability of a randomized, placebo-controlled trial to 18-months post-treatment. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022. Press Release Xu E, et al. Nat Med. 2022;doi:10.1038/s41591-022-02001-z.

Ver todos los episodios